Defining an evidence-based cutpoint for medication adherence in heart failure - 07/08/11
, Debra K. Moser, DNSc, RN, FAAN a, Marla J. De Jong, RN, PhD, CCNS, CCRN b, Mary Kay Rayens, PhD a, Misook L. Chung, PhD, RN a, Barbara Riegel, DNSc, RN, FAAN c, Terry A. Lennie, PhD, RN aRésumé |
Background |
Despite the importance of medication adherence in heart failure, clinically relevant cutpoints for distinguishing the level of adherence associated with outcomes are unknown.
Objective |
The purpose of this study is to determine the cutpoint above which there is a positive relationship between level of medication adherence and event-free survival.
Methods |
This was a longitudinal study of 135 patients with heart failure. Medication adherence was measured using a valid and objective measure, the Medication Event Monitoring System. Two indicators of adherence were assessed by the Medication Event Monitoring System (AARDEX, Union City, CA): (1) dose count, percentage of prescribed doses taken, and (2) dose days, percentage of days the correct number of doses was taken. Patients were followed up to 3.5 years to collect data on outcomes. A series of Kaplan-Meier plots with log-rank tests, Cox survival analyses, and receiver operating characteristic curves were assessed comparing event-free survival in patients divided at one-point incremental cutpoints.
Results |
Event-free survival was significantly better when the prescribed number of doses taken (dose count) or the correct dose (dose day) was ≥88%. This level was confirmed in a Cox regression model controlling for age, gender, ejection fraction, New York Heart Association, comorbidity, angiotensin-converting enzyme inhibitor use, and β-blocker use. Receiver operating characteristic curves showed that adherence rates above 88% produced the optimal combination of sensitivity and specificity with respect to predicting better event-free survival. With 88% as the adherence cutpoint, the hazard ratio for time to first event for the nonadherent group was 2.2 by dose count (P = .021) and 3.2 by dose day (P = .002).
Conclusion |
The results of this study provide clinicians and researchers with an evidence-based recommendation about the level of adherence needed to achieve optimal clinical outcomes.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by funding from the Philips Medical-American Association of Critical Care Nurses Outcomes Grant, University of Kentucky General Clinical Research Center (M01RR02602), grant R01 NR008567 from the National Institute of Nursing Research, and a center grant to the University of Kentucky College of Nursing from NIH, NINR, 1P20NR010679. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. |
|
| The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Air Force or the Department of Defense. |
Vol 157 - N° 2
P. 285-291 - février 2009 Retour au numéro
Article précédent
- A multifaceted intervention to improve blood pressure control: The Guideline Adherence for Heart Health (GLAD) study
- Denise E. Bonds, Patricia E. Hogan, Alain G. Bertoni, Haiying Chen, C. Randall Clinch, Ann E. Hiott, Erica L. Rosenberger, David C. Goff
- Daily walking performance as an independent predictor of advanced heart failure : Prediction of exercise capacity in chronic heart failure
- Melissa Jehn, Arno Schmidt-Trucksäss, Tibor Schuster, Michael Weis, Henner Hanssen, Martin Halle, Friedrich Koehler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?